Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Hiroyuki Takamatsu; Takeshi Yamashita; Shingo Kurahashi; Takayuki Saitoh; Tadakazu Kondo; Takeshi Maeda; Hideyuki Nakazawa; Makoto Murata; Tomoko Narita; Junya Kuroda; Hisako Hashimoto; Koji Kawamura; Toshihiro Miyamoto; Sumihisa Honda; Tatsuo Ichinohe; Yoshiko Atsuta; Kazutaka Sunami

doi:10.1016/j.bbmt.2018.11.003

Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Biol Blood Marrow Transplant. 2019 Mar;25(3):474-479. doi: 10.1016/j.bbmt.2018.11.003. Epub 2018 Nov 10.

Authors

Hiroyuki Takamatsu¹, Takeshi Yamashita², Shingo Kurahashi³, Takayuki Saitoh⁴, Tadakazu Kondo⁵, Takeshi Maeda⁶, Hideyuki Nakazawa⁷, Makoto Murata⁸, Tomoko Narita⁹, Junya Kuroda¹⁰, Hisako Hashimoto¹¹, Koji Kawamura¹², Toshihiro Miyamoto¹³, Sumihisa Honda¹⁴, Tatsuo Ichinohe¹⁵, Yoshiko Atsuta¹⁶, Kazutaka Sunami¹⁷

Affiliations

¹ Department of Hematology/Respiratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan. Electronic address: takamaz@staff.kanazawa-u.ac.jp.
² Department of Hematology/Respiratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan; Division of Internal Medicine, Keiju Kanazawa Hospital, Kanazawa, Japan.
³ Division of Hematology and Oncology, Toyohashi Municipal Hospital, Toyohashi, Japan.
⁴ Department of Hematology, Gunma University Hospital, Maebashi, Japan.
⁵ Department of Hematology/Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
⁶ Department of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan.
⁷ Department of Hematology, Shinshu University School of Medicine, Matsumoto, Japan.
⁸ Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
⁹ Division of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan.
¹⁰ Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
¹¹ Department of Hematology/Division of Stem Cell Transplantation, Kobe General Hospital/Institute of Biomedical Research and Innovation, Kobe, Japan.
¹² Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
¹³ Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
¹⁴ Department of Nursing, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
¹⁵ Department of Hematology and Oncology, Hiroshima University Hospital, Hiroshima, Japan.
¹⁶ Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan; Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan.
¹⁷ Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.

PMID: 30423479
DOI: 10.1016/j.bbmt.2018.11.003

Abstract

Conventional cytogenetic analyses and fluorescent in situ hybridization (FISH) are helpful for stratifying patients with multiple myeloma (MM) into high-risk [t(4;14), t(14;16), and/or del 17p] and standard-risk [t(11;14)] categories. However, the prognosis of patients with MM treated with autologous stem cell transplantation (ASCT) stratified according to these categories remains unclear. This retrospective observational study analyzed 97 patients with MM who received a single, planned ASCT after treatment with 200 mg/m² melphalan between 2001 and 2011. The patients were grouped according to chromosomal abnormality, including t(11;14) (n = 45), t(4;14) (n = 31), del 17p (n = 10), t(11;14) with del 17p (n = 7), and t(4;14) with del 17p (n = 4). Median overall survival (OS) of the t(11;14) group (64.1 months) was not significantly different from that of the t(4;14) group (not reached), but it was significantly longer than that of the del 17p group (23.0 months; P = .002). G-banding revealed that the median OS of the t(11;14) group with additional chromosomal abnormalities (ACAs) (46.2 months) was significantly shorter than that of the t(11;14) group without ACAs (not reached; P = .005) and the t(4;14) group (not reached; P = .010). These findings highlight the importance of G-banding in patients with t(11;14) MM.

Keywords: Autologous stem cell transplantation; Multiple myeloma; t(11;14).

Publication types

Observational Study

MeSH terms

Adult
Aged
Chromosome Aberrations
Chromosomes, Human, Pair 11
Chromosomes, Human, Pair 14
Female
Hematopoietic Stem Cell Transplantation*
Humans
Male
Middle Aged
Multiple Myeloma / diagnosis
Multiple Myeloma / genetics
Multiple Myeloma / therapy*
Prognosis
Retrospective Studies
Risk Assessment
Translocation, Genetic / genetics*
Transplantation, Autologous